MEDG Medgenics(Regs)

TIDMMEDG TIDMMEDU

RNS Number : 4431X

Medgenics Inc

13 January 2014

 
 Press Release   13 January 2014 
 

Director's Dealings

Medgenics, Inc. (AIM: MEDU, MEDG and NYSE MKT: MDGN), the developer of Biopump(TM) , a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that, on 8 January 2014, it was informed by Andrew Pearlman, a Director of the Company who retired as CEO on 13 September 2013, that he exercised options on 8 January 2014 for 45,534 shares at an exercise price of US$2.49 per share and sold a total 45,534 shares of common stock at an average price of US$6.54 per share and, on 9 January 2014 it was informed by Dr. Pearlman that he exercised options on 9 January 2014 for 28,466 shares at an exercise price of US$2.49 per share and 6,000 shares at an exercise price of US$3.14 per share and sold 34,466 shares at an average price of US$6.69 per share, in each case under a personal stock trading plan established in accordance with both the guidelines established by Rule 10b5-1 under the U.S. Securities Exchange Act of 1934, as amended, and the AIM Rules for Companies as well as the Company's policies with respect to insider sales.

The stock was sold for personal financial planning purposes including the payment of taxes in connection with the exercise of stock options. Following these option exercises and sales, Dr. Pearlman owns 42,375 shares of common stock representing approximately 0.2 per cent of the issued share capital. Dr. Pearlman also has the right to purchase up to 1,100,968 shares of common stock pursuant to warrants and options previously granted (in aggregate Dr. Pearlman's shares of common stock, warrants, and options represent 1,143,343 shares of common stock which represent approximately 6.1 per cent of the issued share capital).

This announcement is being made pursuant to the London Stock Exchange's AIM Rules for Companies admitted to trading on the AIM market.

About Medgenics

Medgenics is developing and commercializing Biopump(TM), a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own tissue for the treatment of a range of chronic diseases including anemia, hepatitis, among others. For more information, please visit www.medgenics.com.

Contacts:

 
 Medgenics, Inc. 
  John Leaman, CFO 
  john.leaman@medgenics.com 
 Abchurch Communications 
  Joanne Shears / Jamie Hooper 
  / Harriet Rae 
  harriet.rae@abchurch-group.com      +44 207 398 7718 
 Oriel Securities (NOMAD & Broker) 
  Jonathan Senior / Giles Balleny     +44 207 710 7617 
 
 

-Ends-

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSUUURRSKAAAAR

Medgenics(Regs) (LSE:MEDG)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Medgenics(Regs) (LSE:MEDG)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024